-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SD-101 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SD-101 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SD-101 in Pancreatic Ductal Adenocarcinoma Drug Details: SD-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-442257 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAR-442257 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details: SAR-442257 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SD-101 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SD-101 in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SD-101 in Hepatocellular Carcinoma Drug Details: SD-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SD-101 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SD-101 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SD-101 in...
-
Product Insights
Cardiac Catheters – TriSalus Life Sciences Inc – SUREFIRE
GlobalData, the industry analysis specialist, has released its latest report: Cardiac Catheters - TriSalus Life Sciences Inc - SUREFIRE. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by...
-
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bile Duct Cancer Pipeline Drugs Market Report Overview Bile duct cancer (cholangiocarcinoma) are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers), and weight loss. Treatment includes chemotherapy and radiation therapy. The Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SD-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SD-101 Drug Details SD-101 is under development for the treatment of breast cancer, pancreatic...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
Uveal Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Uveal melanoma symptoms include dark spot on the iris, glaucoma, eye pain, and eye redness. Treatment for the disease includes surgery, radiation, and proton therapy. The Uveal Melanoma pipeline drugs market research report provides an overview of the Uveal Melanoma (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also...